Paclitaxel eluting balloon . More effective in restenosis of BMS than DES

Original title: A multicenter randomized comparison of paclitaxel-coated balloon catheter with conventional balloon angioplasty in patients with bare-metal stent restenosis and drug-eluting stent restenosis. Referencia: Seiji Habara et al. Am Heart J 2013;166:527-533.e2.

Paclitaxel – eluting balloons have recently emerged as an option for treating in-stent restenosis, both conventional stents ( BMS ) and with drugs (DES ). This study randomized patients 2:1 with in-stent restenosis of BMS or DES ( sirolimus , zotarolimus or everolimus) to angioplasty with paclitaxel eluting balloon ( SeQuent Please balloon catheter , B. Braun Melsungen AG , Vascular Systems, Berlin , Germany) versus conventional balloon . The primary objective of the study was a composite of cardiac death , myocardial infarction and target vessel revascularization at 6 months, point when it was scheduled for angiographic protocol follow-up. 

The study included 208 patients ( 137 received eluting balloon and 71 conventional balloons) . Of the total, 123 injuries were due to restenosis of BMS and 90 by DES restenosis . The type of stent restenosis was similar in both treatment branches. The incidence of the combined end point was 6.6 % for drug balloon versus 31% for conventional balloon group ( p < 0.001 ) . This difference was due to target vessel revascularization since no infarctions or deaths were observed in either group.

In the group of drug balloons restenosis in angiographic follow-up was 1.1% for patients who previously had a BMS versus 9.1% for those with a DES ( p = 0.04 ) . This happens despite the fact that BMS had more extensive and diffuse restenosis at baseline than DES. Drug balloon late lumen loss was lower in the BMS than DES ( 0.05 ± 0.28 mm versus 0.18 ± 0.38mm respectively; P = .03) . 

Conclusion:

The paclitaxel – eluting balloons provide better angiographic and clinical outcomes than conventional balloons in patients  with in-stent restenosis both conventional and drug eluting stents

Editorial Comment:

Striking that standard balloon is still used as a control group to treat in-stent restenosis . After ISAR- DESIRE trials became clear that one DES was best for restenosis of BMS , leaving some unknowns still for DES restenosis ( e.g. same or different drugs tested in the ISAR- DESIRE 2). Despite this, the ISAR- DESIRE 3 also included a conventional balloon branch like this study.

Beyond the expected pharmacological superiority of the balloon , it is important to note the different response to the same when it comes to treating a BMS or DES with restenosis.

SOLACI.ORG

More articles by this author

TCT 2024 | FAVOR III EUROPA

The study FAVOR III EUROPA, a randomized trial, included 2,000 patients with chronic coronary syndrome, or stabilized acute coronary syndrome, and intermediate lesions. 1,008...

TCT 2024 – ECLIPSE: Randomized Study of Orbital Atherectomy vs Conventional PCI in Severely Calcified Lesions

Coronary calcification is associated with stent under-expansion and increased risk of both early and late adverse events. Atherectomy is an essential tool for uncrossable...

TCT 2024 | Use of Drug-Coated Balloons for Side Branch Treatment in Provisional Stenting

In some cases, treating coronary bifurcations with provisional stenting requires side branch stenting, which may lead to suboptimal outcomes. Drug-coated balloons (DCBs) have emerged...

TCT 2024 | Use of Artificial Intelligence for Patients with Suspected Coronary Artery Disease

The current approach to chest pain mainly focuses on symptom characteristics, conducting functional tests for ischemia assessment. However, several randomized clinical trials have shown...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

TCT 2024 | FAVOR III EUROPA

The study FAVOR III EUROPA, a randomized trial, included 2,000 patients with chronic coronary syndrome, or stabilized acute coronary syndrome, and intermediate lesions. 1,008...

TCT 2024 | TRISCEND II

This randomized study included 400 patients; 267 were treated with EVOQUE valve and 133 with optimal medical treatment (OMT). After one-year follow-up, there were no...

TCT 2024 – ACCESS-TAVI: Comparing Percutaneous Access Closure Strategies After TAVI

Vascular access complications following transcatheter aortic valve implantation (TAVI) remain common. However, few studies compare vascular access closure methods.  Based on the CHOICE-CLOSURE and MASH...